SK Biopharmaceuticals (326030) Fundamentals 2026 — P/E 17.9x, Revenue Analysis | SniperIQ
SK Biopharmaceuticals (326030) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩6.01T, trading at ₩76800.00 on the KSC. This SniperIQ fundamentals page covers SK Biopharmaceuticals's valuation (P/E 17.9x, P/B 6.3x), profitability (net margin 44.1%), revenue (₩706.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is SK Biopharmaceuticals's market cap?
SK Biopharmaceuticals (326030) has a market capitalization of approximately ₩6.01T, trading at ₩76800.00 on the KSC. Market cap moves with the live share price.
What is SK Biopharmaceuticals's P/E ratio?
SK Biopharmaceuticals's trailing twelve-month P/E ratio is 17.9x, with a price-to-book (P/B) of 6.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is SK Biopharmaceuticals?
SK Biopharmaceuticals runs a net profit margin of 44.1%, a gross margin of 92.2%, and an operating margin of 33.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does SK Biopharmaceuticals generate?
SK Biopharmaceuticals reported revenue of ₩706.7B for fiscal year 2025, with net income of ₩267.0B and earnings per share (EPS) of 3408.75. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does SK Biopharmaceuticals pay a dividend?
SK Biopharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is SK Biopharmaceuticals financially healthy?
SK Biopharmaceuticals carries a debt-to-equity ratio of 0.05x and a current ratio of 2.49x, with a market beta of 0.70. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is SK Biopharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For SK Biopharmaceuticals (326030) the key facts are: market cap ₩6.01T, P/E 17.9x, revenue ₩706.7B, 52-week range 74000-144100. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track SK Biopharmaceuticals's full fundamentals live
Get SK Biopharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.